Claims for Patent: 9,133,162
✉ Email this page to a colleague
Summary for Patent: 9,133,162
Title: | Substituted quinoline compounds and methods of use |
Abstract: | The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans. |
Inventor(s): | Xi; Ning (Newbury Park, CA) |
Assignee: | SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) CALITOR SCIENCES, LLC (Newbury Park, CA) |
Application Number: | 13/400,586 |
Patent Claims: | 1. A compound of Formula (I): ##STR00052## or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable
salt or a prodrug thereof, wherein: R.sup.1 is hydroxy C.sub.2-6 alkoxy; R.sup.2 is H, alkoxy, or hydroxyalkoxy; R.sup.3 is H or F; R.sup.4 is H, F, Cl, Br, I, CN, alkyl, haloalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl; and
X is CH or N, wherein at least one of R.sup.1 and R.sup.2 is hydroxyalkoxy.
2. The compound according to claim 1, wherein R.sup.3 is H or F; R.sup.2 is H or methoxy; and R.sup.4 is H, F, Cl, Br, I, CN, C.sub.1-3 haloalkyl, C.sub.2-5 heterocyclyl, C.sub.2-5 heterocyclyl C.sub.1-3 alkyl, C.sub.3-6 cycloalkyl, or C.sub.3-6 cycloalkyl C.sub.1-3 alkyl. 3. The compound according to claim 1, wherein R.sup.2 is H or methoxy; R.sup.3 is H or F; R.sup.4 is H or F; and X is CH. 4. The compound according to claim 1, wherein R.sup.2 is H; R.sup.3 is H or F; R.sup.4 is H; and X is CH. 5. The compound of claim 1 having one of the following structures: ##STR00053## ##STR00054## ##STR00055## or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. 6. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof. 7. The pharmaceutical composition according to claim 6 further comprising a therapeutic agent selected from a chemotherapeutic agent, an anti-proliferative agent, an agent for treating atherosclerosis, an agent for treating lung fibrosis, and combinations thereof. 8. The pharmaceutical composition according to claim 7, wherein the additional therapeutic agent is adriamycin, rapamycin, temsirolimus, everolimus, ixabepilone, gemcitabin, cyclophosphamide, dexamethasone, etoposide, fluorouracil, afatinib, alisertib, amuvatinib, axitinib, bosutinib, brivanib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, danusertib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motesanib, neratinib, niraparib, nilotinib, oprozomib, olaparib, pazopanib, pictilisib, ponatinib, quizartinib, regorafenib, rigosertib, rucaparib, ruxolitinib, saracatinib, saridegib, sorafenib, sunitinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, vemurafenib, vismodegib, volasertib, an interferon, carboplatin, topotecan, taxol, vinblastine, vincristine, temozolomide, tositumomab, trabedectin, belimumab, bevacizumab, brentuximab, cetuximab, gemtuzumab, ipilimumab, ofatumumab, panitumumab, ranibizumab, rituximab, tositumomab, trastuzumab or a combination thereof. |
Details for Patent 9,133,162
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2031-02-28 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2031-02-28 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2031-02-28 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2031-02-28 |
Glaxosmithkline Llc | BEXXAR | tositumomab and iodine i-131 tositumomab | Injection | 125011 | 06/27/2003 | ⤷ Try a Trial | 2031-02-28 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2031-02-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.